Abstract: Metformin plus megestrol acetate (MA) may be a potential alternative therapy for treating endometrial atypical hyperplasia (EAH). This pilot study suggests that the addition of metformin significantly improves response rates and that the metabolic syndrome (MS) status of patients may have no effect on the efficacy of the combination therapy.
Introduction
Endometrial atypical hyperplasia (EAH) is a significant clinical concern as a known precursor to endometrial cancer. While the standard treatment is surgical removal of the uterus, this is not an option for young women who wish to preserve their fertility. Current conservative management relies on high-dose progestins like megestrol acetate (MA). However, progestin therapy is often slow-acting—requiring up to 18 months for a response—and can cause severe side effects such as weight gain and liver dysfunction.
Given that EAH is strongly linked to insulin resistance and metabolic disorders, researchers hypothesized that combining MA with metformin—a common insulin sensitizer with potential anti-cancer properties—could provide a faster, safer, and more effective treatment.
Methods
This single-blinded, prospective cohort pilot study enrolled premenopausal women (aged ≤45) diagnosed with EAH who desired fertility preservation. Patients were randomized into two groups:
- Control (MA group): 160 mg of oral MA daily.
- Treatment (MET group): 160 mg of oral MA daily plus 1.5 g of oral metformin daily.
The primary endpoint was evaluated at 12 weeks via histological examination of tissue samples obtained through dilation and curettage (D&C). Responses were categorized as Complete Response (CR), Partial Response (PR), or No Response (NR).
Key Results
At the 12-week mark, the study observed a highly promising clinical trend. The MET group achieved a 75% Complete Response (CR) rate (6 out of 8 patients), compared to only 25% (2 out of 8 patients) in the MA-only group.
While the difference in CR rates was clinically substantial, it did not reach standard statistical significance ($p = 0.105$) due to the small sample size. A power analysis (0.518) confirmed the study was underpowered to prove statistical certainty.
Interestingly, the efficacy of the combination therapy appeared independent of metabolic syndrome (MS) status. In the MET group, the CR rate remained 75% regardless of MS status. In contrast, in the MA-only group, 50% of patients with MS achieved CR, while 0% of patients without MS achieved CR. Safety was high across both groups, with only mild, self-resolving nausea reported by three patients in the metformin group.
Discussion and Conclusion
The addition of metformin to standard progestin therapy represents a potential breakthrough for fertility-sparing EAH treatment. By targeting the underlying metabolic environment, this combination therapy may drastically reduce treatment time from over a year to just three months. This reduction significantly improves quality of life and narrows the window of anxiety for patients seeking to conceive.
While limited by a small cohort and a short follow-up period, these findings suggest that metformin may act directly on endometrial tissue to inhibit cell proliferation. Larger, multi-center randomized trials are necessary to confirm these results and track long-term pregnancy outcomes and relapse rates.
Summary updated